Depixus will be participating in the 6th Annual RNA-Targeted Drug Discovery Summit from 12 to 14 December, 2023, Boston, USA.

As one of the most anticipated events on the RNA calendar, the RNA-Targeted Drug Discovery Summit returns this December. This premier, definitive, and most comprehensive forum for the RNA-targeting small molecule community will address remaining challenges, including but not limited to RNA structure and function relationship, functional validation, and the translational route from discovery to pre-clinical and clinical development.

Dr Pascal Beurdeley, SVP Product Development, will be talking about how Depixus is accelerating the discovery of such novel therapeutics using its powerful new MAGNA™ technology. Don’t miss her presentation, which is entitled ‘Structure-activity relationships: using magnetic force spectroscopy to link in vivo and in vitro data in RNA-targeted small molecule drug discovery.’

Also, Dr Adeline Feri (Principal Scientist, Product Development) will be presenting a poster entitled ‘Single molecule real-time analysis of dynamic nucleic acid interactions’.

Depixus will be participating in the International SLAS Conference, from 3 to 7 February, 2024, Boston Convention & Exhibition Center, USA.

This will be a really exciting event for us for 3 reasons:

1. Depixus has been awarded the highly competitive, prestigious, Innovation AveNEW award by SLAS. The SLAS judges assess submission based upon compelling science & technology, clarity of vision & market opportunity, impact on the field of laboratory automation & technology, strength of the management team, and start-up status.
2. Gordon Hamilton, our CEO, is giving an invited talk entitled ‘MAGNA™: A novel single molecule approach for the real-time analysis of biomolecular interactions using magnetic force spectroscopy’
3. We are launching our ground-breaking MAGNA One™ instrument, which you will see at our Innovation AveNEW booth 846A!

SLAS is a global, non-profit professional community made up of scientists from academia, government and industry who are collectively focused on leveraging the power of technology to achieve scientific objectives. A primary part of their mission is to unite great minds in life sciences and technology to transform research.

Gordon Hamilton, CEO of Depixus will be participating in AGBT 2024 in Orlando, Florida, from 5 to 6 February.

Advances in Genome Biology and Technology (AGBT) is considered the preeminent genome science and technology conference where top global researchers, leaders and innovators meet to announce new discoveries, cutting edge breakthroughs and to collaborate.

As a recognized cornerstone for the genomics research community, AGBT provides an outstanding forum for exchanging information about the latest advances in the study of DNA, experimental and analytical approaches for genomic studies, and their myriad applications.

Depixus will be exhibiting its ground-breaking MAGNA One™ instrument at the Biophysical Society Annual Meeting, from 10 to 14 February, 2024, Pennsylvania Convention Center, Philadelphia, USA.

The theme of this year’s meeting is very appropriate: Biophysics: The Next Generation

As science becomes increasingly interdisciplinary, the Biophysical Society Annual Meeting continues its long-held reputation for bringing together leading scientists from all over the world who work at the interface of the life, physical, and computational sciences. The meeting shares the latest unpublished findings of leading research groups worldwide, as well as highlighting the newest emerging techniques and applications.

Depixus will be exhibiting its ground-breaking MAGNA One™ instrument at Booth #309 at the Drug Discovery Chemistry Conference from 1 to 4 April, 2024, San Diego, USA.

Drug Discovery Chemistry highlights advances in current and emerging “hot” targets and technologies, as well as target validation strategies for the discovery and development of novel therapeutic agents ranging from biologics to small molecules.

We look forward to seeing you there!

Depixus will be exhibiting its ground-breaking MAGNA One™ instrument at Booth #515 at the Discovery on Target Conference from 30 September to 3 October, 2024, Boston, USA.

Discovery on Target (DOT) is a dynamic conference for medicinal and biophysical chemists working in pharma, biotech, and academia. Focused on discovery and optimization challenges of small molecule drug candidates, this event provides cutting edge coverage of hot new areas such as small molecules targeting RNA, protein degraders, molecular glues, and artificial intelligence for early drug discovery.

We look forward to seeing you there!